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Abstract
Background: High dose of corticosteroids has been previously shown to protect against controlled mechanical
ventilation (CMV)-induced diaphragmatic dysfunction while inhibiting calpain activation. Because literature suggests
that the calpain inhibiting effect of corticosteroid depends on the dose administered, we determined whether
lower doses of corticosteroids would also provide protection of the diaphragm during CMV. This may be important
for patients undergoing mechanical ventilation and receiving corticosteroids.
Methods: Rats were assigned to controls or to 24 hours of CMV while being treated at the start of mechanical
ventilation with a single intramuscular administration of either saline, or 5 mg/kg (low MP) or 30 mg/kg (high MP)
of methylprednisolone.
Results: Diaphragmatic force was decreased after CMV and this was exacerbated in the low MP group while high
MP rescued this diaphragmatic dysfunction. Atrophy was more severe in the low MP group than after CMV while
no atrophy was observed in the high MP group. A significant and similar increase in calpain activity was observed
in both the low MP and CMV groups whereas the high dose prevented calpain activation. Expression of
calpastatin, the endogenous inhibitor of calpain, was decreased in the CMV and low MP groups but its level was
preserved to controls in the high MP group. Caspase-3 activity increased in all CMV groups but to a lesser extent
in the low and high MP groups. The 20S proteasome activity was increased in CMV only.
Conclusions: Administration of 30 mg/kg methylprednisolone during CMV protected against CMV-induced
diaphragm dysfunction while 5 mg/kg was more deleterious. The protective effect is due mainly to an inhibition of
the calpain system through preservation of calpastatin levels and to a lesser extent to a caspase-3 inhibition.
Background
Corticosteroids are among the most widely used drugs
in the world and are effective in the treatment of many
inflammatory and immune diseases. However, one of
the main side-effects of systemically administered corti-
costeroids is skeletal muscle myopathy, involving
respiratory as well as peripheral muscles. The incidence
of steroid-induced myopathy varies from 7% [1] to 60%
[2] in patients receiving glucocorticoid treatment for
various diseases. Glucocorticoids have been shown to
cause mainly atrophy of fast-twitch type II muscle fibers
with less or no impact on type I fibers [3]. In skeletal
muscle, glucocorticoids decrease the rate of muscle pro-
tein synthesis and increase the rate of muscle proteolysis
[4]. The stimulatory effect of corticosteroids on muscle
proteolysis results from the activation of the proteolytic
systems such as the ubiquitin-proteasome system (UPS),
the lysosomal system, the calcium-dependent calpain
system and the caspase-3 system [5,6].
Although the effects of corticosteroids on muscle pro-
teolysis are well documented, the protective effect of
corticosteroids on protein degradation is less recognized.
In some circumstances, corticosteroids have been shown
t oi n h i b i tt h ec a l p a i ns y s t e m[ 7 - 1 0 ]a n dt h ec a s p a s e - 3
system [11-13]. For calpain, in vitro degradation of neu-
rofilament proteins from rat spinal cord homogenates
through calpain activation, was substantially inhibited by
corticosteroids in a dose-dependent fashion [7]. Also, in
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ment with prednisolone (10m g / k g ,c o r r e s p o n d i n g
~1.6 mg/kg in humans) abolished calpain activation in
the liver [14]. Interestingly, in this study the calpain-
inhibiting effect of corticosteroids was shown to depend
on the dose administered, being minimal at low concen-
trations. Recently our group showed that administration
of a single high dose of methylprednisolone (80 mg/kg,
corresponding ~13 mg/kg in humans) during controlled
mechanical ventilation protected the diaphragm from
the deleterious effects of prolonged mechanical ventila-
tion through inhibition of the calpain system [9]. This
study and a previous CMV study, in which we used a
calpain inhibitor [9], confirm the important role of the
calpain system in the development of VIDD. It is known
that three major proteolytic systems are upregulated in
the diaphragm during mechanical ventilation: the ubi-
quitin proteasome system (UPP), the Ca
2+-dependent
calpain system and the lysosomal system [15-17].
Although the UPP is considered a major proteolytic sys-
tem in skeletal muscle, it cannot degrade intact myo-
filaments. Release of myofilaments for subsequent
degradadtion by the UPP occurs by the calpain and/or
caspase system and may be the rate-limiting step in ske-
letal muscle proteolysis [18].
In regard to patients undergoing prolonged mechani-
cal ventilation, it is important to know whether lower
doses of corticosteroids, as used in the clinical practice,
can also provide protection against mechanical ventila-
tion-induced diaphragmatic weakness.
Since the literature supports the fact that the calpain-
inhibiting effect of corticosteroids depends on the dose
administered, the aim of the present study was to deter-
mine whether administration of lower doses of corticoster-
oids would provide protection against ventilator-induced
diaphragm dysfunction (VIDD).
Methods
Experimental procedure
Male Wistar rats were randomly assigned to one of four
experimental groups: control (C, n = 9), 24 hours of
mechanical ventilation receiving an intramuscular injec-
tion of saline (CMV, n = 9) or methylprednisolone (MP)
at a low dose (5 mg/kg, MP-5, n = 7) or at high dose (30
mg/kg, MP-30, n = 6). The study was approved by the ani-
mal experiments committee of the Medical Faculty of the
Katholieke Universiteit Leuven. Rats were tracheotomized
and the jugular vein was cannulated for continuous infu-
sion of Pentobarbital. A catheter was inserted into the
carotid artery to permit continuous blood pressure mea-
surements and the collection of blood to measure blood
gases. Body temperature was continuously maintained at
37°C. Rats received an intramuscular injection of either
saline or methylprednisolone (5 mg/kg, corresponding
~0.8 mg/kg in humans [19]) or 30 mg/kg, (corresponding
~4.8 mg/kg in humans [19]) at the start of the 24 h
mechanical ventilation protocol. The doses of methylpred-
nisolone were pharmacologically scaled to the animal’s
metabolic rate which makes the dose compatible with
human dosages. Appropriate conversion of drug doses
from animal to humans can be calculated as previously
recommended [19]. Upon completion of mechanical venti-
lation, the diaphragm was quickly excised and a strip was
used for in vitro contractile properties, as described pre-
v i o u s l y[ 2 0 ] ,w h i l et h er e m a i n i n gp a r tw a sf r o z e nf o r
further analysis.
Histochemistry
Serial sections of the costal diaphragm were stained with
hematoxylin and eosin and for myofibrillar adenosine
triphosphatase to determine cross-sectional area (CSA)
and proportion of the fibers, as described previously
[20].
Western blot
Talin, aII-spectrin and calpastatin, the endogenous inhibi-
tor of calpain I and II, were measured by western blotting.
Proteolysis of talin, a preferential intracellular substrate of
calpain, was investigated as an indirect measurement of
calpain activity. Measurement of the caspase-3 mediated
cleavage of aII-spectrin was used to assess caspase-3 activ-
ity. Diaphragm was homogenized in a buffer containing
100 mM KPO4 and total protein concentration was deter-
mined with the Bradford method. Proteins were separated
on a polyacrylamide gel and transferred onto a polyvinyl-
difluoride membrane. Blots were incubated overnight at
4°C with a primary antibody against talin (Sigma), calpas-
tatin (Sigma) or aII-spectrin (Tebu-Bio) and with the
appropriate secondary antibodies. For calpastatin, data
were corrected for alpha-tubulin (Sigma) to ensure equal
loading. Since calpain activity and caspase-3 activity are
expressed as the ratio between breakdown products and
intact protein, corrections for equal loading with alpha-
tubulin were not performed. Ponceau S staining was
performed for each blot to ensure proper transfer of the
proteins. Proteins were visualized with ECL (Amersham)
and analyzed with the software package (Bio 1D) of the
imaging system (Photo print, Vilber, France).
20S proteasome activity
To determine the impact of our experimental treatments
on proteasome activation in the diaphragm, we used a
well-established kinetic fluorometric assay [21].
Statistical analysis
Statistical analysis was performed with the GraphPad
prism software (version 4.01, GraphPad, San diego, CA,
USA). Population distribution was evaluated with the
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p a r i s o n sb e t w e e nt h eg r o u p sw e r em a d eb yao n e - w a y
analysis of variance. When appropriate, a Newman-
Keuls Multiple Comparison Test was performed post
hoc. Correlation analyses were performed using Pear-
son’s coefficient of correlation. Significance was estab-
lished at p < 0.05. Values are reported as mean ± SD.
Results
Systemic and biologic response to CMV
Arterial blood pressure was similar between the 4
groups. Blood pH, PO2 and PCO2 were maintained
within the normal levels and were not different between
the groups (Table 1).
Diaphragm in vitro contractile properties
In the CMV group the force-frequency curve shifted
downwards when compared to C, as previously shown
(Figure 1 upper panel). In the MP-5 group, diaphragm
force was further reduced compared to C and MP30. By
contrast in the MP-30 group, diaphragm force was simi-
lar to that of C at all stimulation frequencies. Tetanic
tension was decreased with 30% after CMV when com-
pared to C and with an additional 15% in the MP-5
g r o u p( p<0 . 0 1v so t h e r s )w h i l ei tw a su n c h a n g e di n
the MP-30 group (Figure 1 lower panel).
Histochemistry
Proportions of the different fiber types were similar
between all groups. Compared to C, diaphragm CSA of
the type IIx/b fibers was significantly decreased with
29% after CMV, as previously shown, and with an addi-
tional 16% in the MP-5 group. CSA of the type IIa
fibers were decreased in the MP-5 group only (-31%
vs C, p < 0.01) (Figure 2). In the MP-30 group CSA of
the different fiber types remained unchanged and
similar to that of C.
Western blot analysis of calpain, calpastatin and caspase-3
Calpain activity, measured by talin degradation, was sig-
nificantly elevated after CMV, as previously shown, and
to a similar extent in the MP-5 group when compared
to C (Figure 3). In the MP-30 group, talin degradation
was similar to control levels.
Calpastatin levels were significantly and similarly
decreased after CMV and after administration of 5 mg/kg
MP compared with controls (Figure 4). In the MP-30
group, calpastatin expression was similar to that of the
control group.
Analysis of the caspase-3 mediated cleavage of aII-
spectrin revealed that CMV induced a significant rise in
caspase-3 activity when compared to C (+149%, p <
0.001). Caspase-3 activity was similarly increased in the
MP-5 and the MP-30 group (+96% and +78% respec-
tively, p < 0.05 vs C) but this increase was significantly
less compared to that of CMV (Figure 5).
Significant negative correlations were found between
calpain activity and diaphragm force (-0.50<r < -0.41,
p < 0.05) as well as with CSA of the type IIx/b fibers
Table 1 Blood gas data and arterial blood pressure
PaO2 (mmHg) PaCO2 (mmHg) pH PA (mmHg)
CMV 148 ± 56 26 ± 4 7.57 ± 0.10 94 ± 29
MP-5 148 ± 59 34 ± 12 7.51 ± 0.12 95 ± 22
MP-30 121 ± 61 35 ± 10 7.45 ± 0.14 131 ± 31
Blood gases and arterial blood pressure in animals under controlled
mechanical ventilation treated with either saline (CMV) or with 5 mg/kg
methylprednisolone (MP-5) or 30 mg/kg of methylprednisolone (MP-30). For
the control (C) group no hemodynamic measurements are available. Values
are mean ± SD.
Figure 1 Diaphragm force generation. Upper panel: Force-
frequency relationship in the diaphragm of controls (C, open
rectangles, n = 9), controlled mechanical ventilation animals treated
either with saline (CMV, closed triangles, n = 9) or with 5 mg/kg
methylprednisolone (MP-5, open circles, n = 7) or 30 mg/kg
methylprednisolone (MP-30, closed circles, n = 6). Maximal tetanic
tension in the diaphragm of C, CMV, MP5 and MP30 groups. Values
are means ± SD. *p < 0.001 CMV and MP-5 vs others, #p < 0.01
CMV vs C and MP-30, ++p < 0.01 MP-5 vs MP-30, +p < 0.05 MP-5
vs MP-30.
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observed between calpastatin and diaphragm force
(0.43<r < 0.54, p < 0.05) and calpastatin and CSA of the
type IIx/b fibers (r = 0.57, p < 0.02).
20S proteasome activity
Compared to control, the chymotrypsin-like activity of
the 20S proteasome was increased (p < 0.05) by 48% in
diaphragms from the CMV group. In contrast, both the
low dose (MP-5) and high dose (MP-30) of corticoster-
oids prevented the CMV-induced proteasome activation
in the diaphragm.
Discussion
Overview of principle findings
This is the first study to demonstrate that the protective
effect of corticosteroids against VIDD depends on the
dose administered and results mainly from an inhibition
of the calpain system and to a lesser extent from a
reduction in caspase-3 activation. Administration of
relatively low dose of methylprednisolone (5 mg/kg)
resulted in an exacerbation of diaphragm dysfunction
and atrophy. None of these effects were observed with
the higher dose of methylprednisolone (30 mg/kg), a
dose that fully protected the diaphragm against the
effects of CMV.
Corticosteroids and skeletal muscle
Corticosteroids are known to decrease muscle synthesis
and to accelerate protein degradation [4]. In vivo
Figure 2 Diaphragm cross-sectional area of the different fiber
types. Diaphragm cross-sectional area (CSA) of the type I, IIa and
IIx/b fibers in the controls (C, n = 6) and controlled mechanical
ventilation animals treated either with saline (CMV, n = 6) or with
5 mg/kg methylprednisolone (MP-5, n = 6) or 30 mg/kg
methylprednisolone (MP-30, n = 5). Values are means ± SD. *p <
0.05 vs C and MP-30, #p < 0.05 vs CMV, +p < 0.01 vs C.
Figure 3 Western blot analysis of talin. Upper panel: A representative western blot for the analysis of intact and cleaved talin (BDP) in the
diaphragm of controls (C, n = 6) and controlled mechanical ventilation with saline injection (CMV, n = 9) or with 5 mg/kg methylprednisolone
(MP-5, n = 7) or 30 mg/kg methylprednisolone (MP-30, n = 5). Lower panel: Mean densitometric values for talin degradation by calpain. Values
are shown as the ratio of degraded talin to intact protein and are expressed as means ± SD, *p < 0.05 vs others.
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shown to stimulate the different proteolytic systems
[22-26]. On the other hand, there are also evidences
suggesting that corticosteroids may provide beneficial
effects on skeletal muscles. In patients with Duchenne
muscular dystrophy, treatment with prednisolone signifi-
cantly improved muscle strength and this beneficial
effect appeared to be associated with an increase in
muscle mass probably mediated by inhibition of muscle
proteolysis rather than by stimulation of muscle protein
synthesis [27]. Inhibition of muscle proteolysis, in parti-
cular the calpain system, by corticosteroids has been
suggested in several in vitro [7,19,28,29] and in vivo
[14,30,31] studies. In addition, treatment with methyl-
prednisolone has been shown to reduce caspase-3
mRNA and protein expression in several animal
models [11-13].
Corticosteroids and the calpain system
The ability of corticosteroids to inhibit calpain seems to
depend on the dose administered. An in vitro study
showed that methylprednisolone was slightly effective at
low concentrations while more than 80% of calpain inhi-
bition was observed with high concentrations [7]. This
was also confirmed in several in vivo studies where dif-
ferent doses of corticosteroids were administered to ani-
mals. In rabbits, calpain activation caused by hypoxia
was prevented by betametasone pretreatment, indicating
inhibition of calpain activation [30]. In a rat model
of ischemia-induced liver injury pretreatment of animals
with 10 mg/kg of prednisolone (corresponding
~1.6 mg/kg in humans [19]) significantly inhibited cal-
pain activation in the liver while lower doses (1 mg/kg,
Figure 4 Western blot analysis of calpastatin. Upper panel: A representative western blot for calpastatin and a-tubulin in the diaphragm of
controls (C, n = 6) and controlled mechanical ventilation with saline injection (CMV, n = 8) or with 5 mg/kg methylprednisolone (MP-5, n = 7)
or 30 mg/kg methylprednsiolone (MP-30, n = 5). Lower panel: Densitometric values for calpastatin corrected for a-tubulin. Values are means ±
SD, *p < 0.05 vs others.
Figure 5 Western blot analysis of aII-spectrin. Densitometric
values for aII-spectrin degradation by caspase-3. Values are shown
as the ratio of degraded aII-spectrin to intact protein and are
expressed as means ± SD, *p < 0.01 vs C, #p < 0.05 vs CMV.
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corresponding ~0.5 mg/kg in humans [19]) did not [8].
Also a dose of 30 mg/kg of corticosteroids administered
to piglets (corresponding ~6.5 mg/kg in humans [19])
before and during cardiopulmonary bypass was able to
reduce the percentage of degraded troponin I while pre-
serving calpastatin activity levels [31]. This is interesting
knowing that the dose of 30 mg/kg is currently used in
patients undergoing cardio-pulmonary bypass [32-34].
The precise mechanisms by which corticosteroids
inhibit calpain activity remain unclear. Nonetheless,
based upon our current knowledge regarding calpain
regulation, a bride discussion of calpain regulation in
the diaphragm during prolonged CMV is warranted.
Calpain is a Ca
2+-dependent cytosolic protease which is
typically in an inactive state under basal conditions. Cal-
cium is the most important activator of calpain. Binding
of calcium to calpain leads to conformational changes of
the molecule allowing activation of its catalytic site. An
additional important regulator of calpain activity is its
endogenous inhibitor calpastatin [18]. Evidence exists
that corticosteroids might protect against calpain activa-
tion by preventing an increase in cytosolic calcium
levels. In mdx muscle fibers, a condition in which cyto-
solic Ca
2+ is increased, treatment with methylpredniso-
lone attenuated the rise in cytosolic free calcium
following hypo-osmotic stress [35]. On the other hand,
preservation of calpastatin levels was associated with
calpain inhibition after MP treatment in a piglet model
of cardiopulmonary bypass [31]. Therefore, in the cur-
rent experiments, it is possible that the MP treatment
inhibited CMV-induced calpain activation in the dia-
phragm by preventing an increase in cytosolic Ca
2+
levels, preservation of calpastatin levels, or some combi-
nation of both. Additional experiments will be required
to provide a complete understanding of this issue.
Corticosteroids and mechanical ventilation
Animal studies have clearly demonstrated that CMV
impacts the diaphragm by promoting contractile dys-
function, increased proteolysis and atrophy [17,36].
Interestingly, our results reveal that administration of a
relatively low dose of methylprednisolone (5 mg/kg, cor-
responding ~0.8 mg/kg in humans [19]) exacerbates the
CMV-induced diaphragm dysfunction, whereas a higher
dose (30 mg/kg, corresponding ~5 mg/kg in humans
[19]) completely protected the diaphragm against VIDD.
The dose-depending effect of corticosteroids are in
agreement with previous studies [7,8,31]. Our finding of
a negative correlation between calpain activity and either
diaphragmatic force production or diaphragm fiber CSA
further supports the notion that calpain activation plays
an important role in CMV-induced diaphragmatic atro-
phy and contractile dysfunction. In our previous study
we also showed that administration of 80 mg/kg (corre-
sponding ~13 mg/kg in humans [19]) of MP during
CMV protected against VIDD [9]. By contrast, CMV in
combination with 80 mg/kg of MP in rabbits (corre-
sponding ~28 mg/kg in humans [19]) showed no pro-
tection of VIDD after 1, 2 or 3 days of CMV [37]. It is
unclear whether the discrepancy between our results
and this work is related to species differences (rat vs
rabbit) or to the duration of MP treatment. Further-
more, the present study also identified a potential role
for calpastatin, the endogenous inhibitor of calpain, in
the protective effect induced by corticosteroids during
prolonged CMV. The positive correlation found in our
study between calpastatin and diaphragm force or fiber
dimensions further stress the potentially important role
of calpastatin in this model. Inhibition of calpain by MP
through a preservation of calpastatin levels has been
previously reported in a model of cardiopulmonary
bypass [31]. These findings coupled with our data sug-
gest that high doses of corticosteroids may prevent loss
of calpastatin and therefore prevent the activation of cal-
pain in skeletal muscle. It is also possible that the way
MP preserves diaphragm function during controlled
mechanical ventilation might be related to intracellular
cellular calcium levels. Indirect evidence suggests that
p r o l o n g e dC M Vr e s u l t si na ni n c r e a s ei ni n t r a c e l l u l a r
calcium levels in the diaphragm [15]. Therefore protec-
tion against CMV-induced increases in intracellular cal-
cium levels and/or increasing calpastatin binding to
calpain could be potential mechanisms by which corti-
costeroids prevent activation of the protease calpain and
protect against VIDD. Both of these mechanisms have
been proposed to explain the calpain inhibiting effect of
prednisolone in the ischemic liver [14] and this protec-
tive effect of corticosteroids was shown to be dependent
on the dose administered.
Surprisingly, our data showed a prevention of the
CMV-induced increase in 20S proteasome activity with
both doses of MP. This is in contrast with previous lit-
erature showing increases of several components of the
ubiquitin proteasome system after corticosteroids treat-
ment in in vitro [6,38] and in animal studies [22,39].
To our knowledge, only one in vitro study has demon-
strated that treatment of cells (i.e., thymocytes) with
dexamethasone decreased proteasome chymotrypsin-like
activity in cell extracts [40]. Inhibition of the 20S pro-
teasome activity, as observed in the present study, might
be due to the fact that animals were treated with only a
single injection of MP while in most other studies ani-
mals were treated repeatedly with corticosteroids.
Finally our data also indicate that caspase-3 activity
was increased in the diaphragm after CMV and also, but
to a lesser extent, after corticosteroids treatment inde-
pendent of the dose used. Inhibition of caspase-3 by
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models [11-13]. Indeed, administration of methylpredni-
solone (30 or 60 mg/kg) to piglets (corresponding ~6.5
or 13 mg/kg in humans [19]) with cardio-pulmonary
bypass resulted in a reduction of myocardial caspase-3
activity [12]. Similar, when 10 mg/kg (corresponding
~1.6 mg/kg in humans [19]) of dexamethasone was
administered to endotoxemic rats, the expression of cas-
pase-3 mRNA in the brain was inhibited [13]. Currently,
the mechanism of the inhibitory effect of steroids on
caspase-3 expression remains unknown. In the present
study, our data indicate that the effects of MP on cas-
pase-3 activity during CMV were independent of the
dose administered. Our data also clearly show that MP
can minimize the deleterious effects of CMV on the dia-
phragm despite the fact that MP treatment did not fully
prevent caspase-3 activation. We interpret these results
as another indication of the main role played by the cal-
pain system in the development of VIDD.
Conclusions
The effects of corticosteroids on the diaphragm during
CMV depend on the dose administered and relatively
high doses of corticosteroids are required to provide
protection against CMV-induced diaphragmatic atrophy
and contractile dysfunction. The mechanism(s) responsi-
ble for high-dose glucocorticoid-induced diaphragmatic
protection are uncertain but may be linked to the ability
of high doses of corticosteroids to inhibit mainly calpain
activity and caspase-3 but to a lesser extent. The effects
on calpain activity may be related to calpastatin expres-
sion levels.
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